Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $21.1 million.

  • Ani Pharmaceuticals' Shares Outstanding (Diluted Average) rose 870.44% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year increase of 870.44%. This contributed to the annual value of $19.3 million for FY2024, which is 617.79% up from last year.
  • Ani Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $21.1 million in Q3 2025, which was up 870.44% from $20.3 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $21.1 million in Q3 2025 and a low of $12.0 million during Q1 2021
  • In the last 5 years, Ani Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $17.9 million in 2023 and averaged $17.1 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 86.65% in 2021, then surged by 3465.76% in 2022.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $12.6 million in 2021, then rose by 29.09% to $16.3 million in 2022, then increased by 11.89% to $18.2 million in 2023, then grew by 6.18% to $19.3 million in 2024, then rose by 9.19% to $21.1 million in 2025.
  • Its last three reported values are $21.1 million in Q3 2025, $20.3 million for Q2 2025, and $20.0 million during Q1 2025.